ESR1 and cancer: Specifically, in the context of the specific TME Stimulation setup that we have used in the present research, measures that inhibit estrogen receptors or TNFα are already in clinical use in malignancy or other diseases [86,87,88]; thus, one could envision their use under specific settings in cancer, which would require careful examination and study in years to come.